Reply to V. Amoroso et al

J Clin Oncol. 2017 May 1;35(13):1488-1489. doi: 10.1200/JCO.2017.71.3875. Epub 2017 Jan 23.

Authors

James C Yao¹, Maurizio Voi¹, Jeremie Lincy¹, Marianne Pavel¹

Affiliation

¹ James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.

PMID: 28113028
DOI: 10.1200/JCO.2017.71.3875

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Everolimus
Humans
Pancreatic Neoplasms*

Substances

Everolimus

Associated data

ClinicalTrials.gov/NCT00510068